Costco Wholesale Corporation vs GeneDx Holdings Corp — how do they compare? Costco Wholesale Corporation trades at $946.92 (market cap $420.05B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Costco Wholesale Corporation is far larger — about 207.9× GeneDx Holdings Corp's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and GeneDx Holdings Corp for 19 Days on average.
| COST | WGS | |
|---|---|---|
Market Cap | $420.05B | $2.02B |
Volume | 2,087,565 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $167.51 |
52-Week Low | $849.63 | $34.51 |
Typical Hold Time | 133 Days | 19 Days |
Enterprise Value | $407.33B | $2.05B |
Dividend Yield | 0.62% | — |
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $947.92, up 0.6% on the day, near its pivot point of $947 with strong analyst consensus. The stock shows bullish moving averages but overbought RSI signals. Recent March sales surged 11.3% year-over-year to $28.41 billion (Costco report, April 8, 2026), while Q2 2026 EPS beat expectations. Valuation remains elevated with a P/E of 45.66, supported by robust membership fee growth and expansion.
Outlook is positive given consistent revenue growth and high renewal rates post-fee hike, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $1,100 implies ~16% upside, with institutional buying underscoring confidence. Key catalysts are Q3 2026 earnings and sustained comp sales momentum.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →